Articles tagged "Rejection"

2016 American Transplant Congress
Treatment of Late Antibody-Mediated Rejection: Observations from Clinical Practice.
G. Einecke,¹ J. Bräsen,² A. Schwarz,¹ H. Haller,¹ F. Njau.¹
¹Nephrology, Medical School of Hannover, Hannover, Germany; ²Pathology, Medical School of Hannover, Hannover, Germany.
Antibody-mediated rejection (AMR) is a major cause of late renal allograft failure. The benefit of treatment of chronic ABMR is unknown. Currently there is no…
2016 American Transplant Congress
Detection of Endothelial Cell Specific Molecule-1 According to Allograft Status After Kidney Transplantation.
J.-W. Seo, S.-Y. Kim, Y.-G. Kim, Y.-H. Jeong, Y.-H. Lee, J.-Y. Moon, T.-W. Lee, C.-G. Ihm, S.-H. Lee.
Division of Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
To investigate urine ESM-1(endothelial cell specific molecule-1) as well as plasma ESM-1 level from renal allograft recipients, we show whether there is the difference of…
2016 American Transplant Congress
Elevation of Peripheral IL-6 in Kidney Transplant Recipients with Antibody Mediated Rejection.
N. Wilson, A. Djamali, R. Redfield.
University of Wisconsin, Madison.
Background: Despite current therapy, antibody mediated rejection (AMR) remains a major cause of kidney allograft loss. IL-6 is a known survival factor of antibody secreting…
2016 American Transplant Congress
Mass Cytometry Reveals NK Cell and T Cell Subsets in Pediatric Liver Transplant Patients with Acute Rejection.
A. Lau,^1,2 K. Haas,¹ T. Shawler,² C. Esquivel,² O. Martinez,² R. Castillo,¹ S. Krams.²
¹Pediatrics, Stanford/LPCH, Palo Alto, CA; ²Surgery, Stanford, Palo Alto, CA.
Proper evaluation of the immune status of liver transplant recipients is crucial for appropriate post-transplant management. Current monitoring of graft function relies mainly on non-specific…
2016 American Transplant Congress
The Impact of One Year Individual or Dual Organ Rejection in Simultaneous Pancreas-Kidney Transplant on Kidney Graft Survival – A UNOS Registry Analysis 2000-2013.
I. Moinuddin,¹ T. Taber,¹ M. Yaqub,¹ O. Adebiyi,¹ M. Mujtaba,¹ J. Chen,² M. Goble,² D. Mishler,¹ J. Fridell,² A. Sharfuddin.¹
¹Medicine/Nephrology, Indiana University, Indianapolis; ²Surgery/Transplant, Indiana University, Indianapolis.
Background: Early Rejection of either organ in Simultaneous Pancreas-Kidney transplants (SPK) is common within the first 1 year. We studied the impact of within 1…
2016 American Transplant Congress
Rapamycin Nanotherapy Delays Heart Transplant Rejection.
M. Braza,¹ M. Lameijer,¹ C. Perez-Medina,¹ T. Reiner,³ M. Nahrendorf,⁴ Z. Fayad,¹ R. Duivenvoorden,¹ J. Ochando,² W. Mulder.¹
¹Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York; ²Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York; ³Radiology, Memorial Sloan-Kettering Cancer Center, New York; ⁴Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston.
Background:In patients, allograft survival requires a cocktail of immunosuppressive drugs, while experimentally antibodies targeting the innate immune system have been shown to induce long-term tolerance,…
2016 American Transplant Congress
Novel Function of CD4⁺ T Cell DEPTOR in Treg Homeostasis and Alloimmunity.
J. Wedel,^1,2 S. Bruneau,^1,2 K. Liu,^1,2 N. Kochupurakkal,^1,2 M. Laplante,³ D. Briscoe.^1,2
¹Division of Nephrology, Boston Children's Hospital, Boston, MA; ²Transplant Research Program, Harvard Medical School, Boston, MA; ³CRIUCPQ, Université Laval, Quebec, Canada.
DEPTOR, a recently described modulator of PI-3K/mTOR signaling, is expressed by CD4+ T cells, and functions to modulate CD4+ Teff cell differentiation. Upon CD4+ T…
2016 American Transplant Congress
Clinical Significance of Non-HLA Antibodies in the Development of Microcirculation Inflammation in Allograft Tissue After Kidney Transplantation.
J. Min,^1,3 H. Lee,^2,3 B. Chung,^1,3 E.-J. Oh,^2,3 C. Yang.^1,3
¹Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ²Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ³Transplant Research Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
The aim of our study is to determine the clinical significance of pre-transplant non-HLA antibodies, mainly those targeting the angiotenin II type I receptor (AT1R)…
2016 American Transplant Congress
Evaluation of the Toxicity Profile of Proteasome Inhibitor-Based Therapy for Antibody Mediated Rejection.
A. Leino,¹ A. Lichvar,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,¹ F. Paterno,¹ R. Alloway,¹ A. Shields,^1,2 E. Woodle.¹
¹U of Cinncinati, Cincinnati; ²The Christ Hospital, Cincinnati.
Background: Experience with bortezomib (BTZ) antibody mediated rejection (AMR) therapy has progressively increased over the past few years. The BTZ toxicity profile in the transplant…
2016 American Transplant Congress
IFN-γ and Contact-Dependent Cytotoxicity Are Rate-Limiting for NK Cells in a Model of Antibody-Mediated Chronic Rejection.
C. Lin,¹ R. Plenter,¹ R. Gill.²
¹Medicine, University of Colorado, Denver, Aurora, CO; ²Surgery, University of Colorado, Denver, Aurora, CO.
BACKGROUND. Natural killer (NK) cells are key components of the innate immune that contribute to acute and chronic graft rejection. After engagement with antibody, NK…